BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 1, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2017

View Archived Issues

Regenxbio initiates phase I trial of gene therapy RGX-314 for wet AMD

Read More

Phase II trial of XEN-801 for acne does not meet efficacy endpoints

Read More

BARDA elects not to exercise options for AEOL-10150 development for ARS and DEARE

Read More

Xeljanz approved in Europe

Read More

AbbVie begins first-in-human trial of ABBV-621

Read More

Dacomitinib shows efficacy against penile squamous cell carcinoma

Read More

Levosimendan does not result in lower 30-day mortality in high risk cardiac surgery patients

Read More

KPR-2579, a novel TRPM8 antagonist for the potential treatment of bladder hypersensitivity

Read More

Erytech and Fox Chase to advance preclinical development of erymethionase for homocystinuria

Read More

Initiation of phase II trial of LN-145 in patients with squamous cell carcinoma of the head and neck

Read More

Epicentre presents phase III efficacy and safety results for oral BRV-PV rotavirus vaccine

Read More

Matinas reports topline phase I data on MAT-2501

Read More

Synergy submits supplemental NDA for Trulance in IBS-C

Read More

Numab and Ono Pharmaceutical enter immuno-oncology research and option agreement

Read More

Oncology Venture to evaluate Eisai drug for potential in-licensing

Read More

Amryt initiates phase III trial of AP-101 for epidermolysis bullosa

Read More

FDA approves Zejula for the maintenance treatment of women with recurrent ovarian cancer

Read More

ImMAGE Biotherapeutics advances immunotherapy for triple-negative breast cancer

Read More

Infectex reports results from phase IIb/III trial of SQ-109 for multidrug-resistant pulmonary TB

Read More

Sumitomo Dainippon Pharma presents Nav1.7 channel blockers

Read More

F. Hoffmann-La Roche AG patents gamma-secretase inhibitors

Read More

FDA grants priority review to Ryanodex NDA to treat exertional heat stroke

Read More

Genentech and F. Hoffmann-La Roche AG divulge PI3Kalpha inhibitors

Read More

European Commission gives conditional approval to DuPont and Dow Chemical Company's merger of equals

Read More

Vaximm updates on lead compound VXM-01 at BIO-Europe Spring

Read More

Foamix reports phase III topline results for FMX-101 in moderate to severe acne

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing